Bio-Techne (TECH) to Post Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is projected to post its Q4 2026 results before the market opens on Wednesday, August 5th. Analysts expect Bio-Techne to post earnings of $0.52 per share and revenue of $314.6510 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.02). The business had revenue of $311.42 million for the quarter, compared to the consensus estimate of $316.11 million. Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.Bio-Techne’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.56 EPS. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Price Performance

Shares of TECH stock opened at $72.07 on Wednesday. Bio-Techne has a 52 week low of $43.19 and a 52 week high of $72.16. The stock has a market capitalization of $11.28 billion, a PE ratio of 104.45, a PEG ratio of 8.53 and a beta of 1.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.18 and a current ratio of 4.49. The stock’s fifty day moving average is $61.56 and its 200-day moving average is $58.89.

Bio-Techne Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Monday, May 18th were given a dividend of $0.08 per share. The ex-dividend date was Monday, May 18th. This represents a $0.32 annualized dividend and a yield of 0.4%. Bio-Techne’s dividend payout ratio is 46.38%.

Institutional Trading of Bio-Techne

Several institutional investors and hedge funds have recently added to or reduced their stakes in TECH. Steward Partners Investment Advisory LLC lifted its position in Bio-Techne by 7.5% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 3,091 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 216 shares during the period. E Fund Management Co. Ltd. grew its position in shares of Bio-Techne by 4.5% during the 2nd quarter. E Fund Management Co. Ltd. now owns 5,497 shares of the biotechnology company’s stock worth $283,000 after buying an additional 235 shares during the period. Kestra Advisory Services LLC grew its position in shares of Bio-Techne by 3.3% during the 4th quarter. Kestra Advisory Services LLC now owns 7,956 shares of the biotechnology company’s stock worth $468,000 after buying an additional 257 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of Bio-Techne by 2.0% during the fourth quarter. Commonwealth Equity Services LLC now owns 13,900 shares of the biotechnology company’s stock worth $817,000 after buying an additional 274 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of Bio-Techne by 0.7% during the third quarter. CANADA LIFE ASSURANCE Co now owns 48,410 shares of the biotechnology company’s stock worth $2,529,000 after buying an additional 360 shares during the last quarter. 98.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Robert W. Baird increased their price objective on shares of Bio-Techne from $49.00 to $73.00 and gave the stock a “neutral” rating in a report on Friday, June 26th. Piper Sandler assumed coverage on shares of Bio-Techne in a research report on Thursday, June 11th. They set a “neutral” rating and a $65.00 target price on the stock. William Blair cut shares of Bio-Techne from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 25th. Stifel Nicolaus set a $50.00 price target on shares of Bio-Techne in a research note on Thursday, May 7th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Bio-Techne from a “buy” rating to a “hold” rating and set a $73.00 price target for the company. in a report on Friday, June 26th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $68.08.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.